 JPMorgan Chase Co. cut its position in shares of Aeglea Bio Therapeutics Inc NASDAQ:AGLE by 32.5 during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,689 shares of the biotechnology companys stock after selling 15,769 shares during the period. JPMorgan Chase Co. owned ... 